Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
Sponsored by argenx
About this trial
Last updated 3 months ago
Study ID
ARGX-113-NIS-2501
Status
Recruiting
Type
Observational
Placebo
No
Accepting
18+ Years
All Sexes
Trial Timing
Started 10 months ago
What is this trial about?
The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and assess the utilization of health care services among adult participants with CIDP who initiate treatment with efgartigimod.
As this is a noninterventional study, treatment choices and decisions will be left to the discretion of participants and their physicians, according to the standard of care.
Each participant will be prospectively followed for up to 2 years from the date of initial administration of efgartigimod.
What are the participation requirements?
Inclusion Criteria
* Aged ≥18 years at time of providing informed consent
* Diagnosed with CIDP
* Planned to be receiving efgartigimod treatment within the CIDP treatment label of efgartigimod in the participant's respective country
* Efgartigimod treatment-naïve at time of screening
Exclusion Criteria
* Polyradiculoneuropathy due to any other cause(s)
* Current participation in any interventional clinical study at time of screening, or planned participation before initiation of efgartigimod